Blood Disorders & Hematology Clinical Trials Update: Week 16, 2026

Published April 17, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

This Phase 3 trial is testing a new combination of teclistamab and daratumumab against current standard treatments for people whose multiple myeloma has come back or not responded to previous therapies. If successful, it may provide a more effective way to control the disease and offer hope for patients needing new options. The study is active but not recruiting, with results expected in the next few years.

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

This Phase 3 trial compares teclistamab alone to standard drug combinations for people with relapsed or refractory multiple myeloma. Teclistamab is a newer treatment that could become an important option for patients who have tried other therapies without success. The study is ongoing but not enrolling new participants, and findings will help guide future treatment choices.

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

This Phase 3 study explores a treatment approach using blinatumomab with gentler chemotherapy for older adults newly diagnosed with a specific type of blood cancer called Philadelphia-negative B-cell precursor acute lymphoblastic leukemia. The goal is to find a treatment that may be safer and just as effective as the current chemotherapy options. The trial is actively recruiting patients worldwide.

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

This Phase 3 trial is testing new drug combinations including talquetamab for people whose multiple myeloma has returned or resisted treatment. These combinations may offer improved disease control for patients needing additional options. The study is currently recruiting at many locations internationally.

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

This Phase 3 trial is focused on infants under one year old with rare and aggressive types of acute leukemia marked by a specific genetic change called KMT2A rearrangement. The study tests blinatumomab, an immunotherapy, aiming to improve survival for these very young patients. It is recruiting participants internationally.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.